Cargando…
New perspective in heart failure management: could myosin activators be the answer?
Heart failure is a worldwide leading cause of hospital admissions. There is a critical need for new methods of management in acute heart failure. The current drug panel available in the treatment of hemodinamically unstable patients is not only limited, but it is also associated with deleterious sid...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Applied Systems srl
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941581/ https://www.ncbi.nlm.nih.gov/pubmed/32309560 http://dx.doi.org/10.15190/d.2014.25 |
_version_ | 1783484568104337408 |
---|---|
author | Andrei, Stefan Iorgoveanu, Corina |
author_facet | Andrei, Stefan Iorgoveanu, Corina |
author_sort | Andrei, Stefan |
collection | PubMed |
description | Heart failure is a worldwide leading cause of hospital admissions. There is a critical need for new methods of management in acute heart failure. The current drug panel available in the treatment of hemodinamically unstable patients is not only limited, but it is also associated with deleterious side effects. Discoveries in the heart failure field seemed to lack an adequate answer and a change in paradigm may be necessary. The cardiac myosin activator omecamtiv mecarbil is a new therapeutic approach that improves the myocardial contractility through an innovative mechanism, avoiding the harmful effects of currently used inotropic agents. Several studies provided us with promising results, but further scientific proofs are needed. |
format | Online Article Text |
id | pubmed-6941581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Applied Systems srl |
record_format | MEDLINE/PubMed |
spelling | pubmed-69415812020-04-17 New perspective in heart failure management: could myosin activators be the answer? Andrei, Stefan Iorgoveanu, Corina Discoveries (Craiova) Perspective Article Heart failure is a worldwide leading cause of hospital admissions. There is a critical need for new methods of management in acute heart failure. The current drug panel available in the treatment of hemodinamically unstable patients is not only limited, but it is also associated with deleterious side effects. Discoveries in the heart failure field seemed to lack an adequate answer and a change in paradigm may be necessary. The cardiac myosin activator omecamtiv mecarbil is a new therapeutic approach that improves the myocardial contractility through an innovative mechanism, avoiding the harmful effects of currently used inotropic agents. Several studies provided us with promising results, but further scientific proofs are needed. Applied Systems srl 2014-12-31 /pmc/articles/PMC6941581/ /pubmed/32309560 http://dx.doi.org/10.15190/d.2014.25 Text en Copyright © 2014, Applied Systems http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Perspective Article Andrei, Stefan Iorgoveanu, Corina New perspective in heart failure management: could myosin activators be the answer? |
title | New perspective in heart failure management: could myosin activators be the answer? |
title_full | New perspective in heart failure management: could myosin activators be the answer? |
title_fullStr | New perspective in heart failure management: could myosin activators be the answer? |
title_full_unstemmed | New perspective in heart failure management: could myosin activators be the answer? |
title_short | New perspective in heart failure management: could myosin activators be the answer? |
title_sort | new perspective in heart failure management: could myosin activators be the answer? |
topic | Perspective Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941581/ https://www.ncbi.nlm.nih.gov/pubmed/32309560 http://dx.doi.org/10.15190/d.2014.25 |
work_keys_str_mv | AT andreistefan newperspectiveinheartfailuremanagementcouldmyosinactivatorsbetheanswer AT iorgoveanucorina newperspectiveinheartfailuremanagementcouldmyosinactivatorsbetheanswer |